Filing Details
- Accession Number:
- 0001127602-16-039308
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-03 16:39:51
- Reporting Period:
- 2016-02-01
- Filing Date:
- 2016-02-03
- Accepted Time:
- 2016-02-03 16:39:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 884731 | Ariad Pharmaceuticals Inc | ARIA | Biological Products, (No Disgnostic Substances) (2836) | 223106987 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1494892 | Frank Haluska | C/O Ariad Pharmaceuticals, Inc. 26 Landsdowne Street Cambridge MA 02139 | Svp, Clinical R&D, Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-02-01 | 29,333 | $0.00 | 151,557 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-02-01 | 16,133 | $4.81 | 135,424 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2016-02-01 | 29,333 | $0.00 | 29,333 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 29,333 | 2024-01-31 | No | 4 | M | Direct |
Footnotes
- Shares were acquired upon vesting of restricted stock units awarded on January 31, 2014.
- Represents shares sold to satisfy withholding tax requirements, pursuant to a Rule 10b5-1 trading plan.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.74 to $4.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
- Each restricted stock unit represents a right to receive one share of ARIAD common stock.
- The restricted stock units vest as to one-third of the units on each of the first, second and third anniversaries of the date of the award (January 31,2014).
Billionaire Hedge Funds
